AUTOLOGOUS ENDOTHELIAL PROGENITOR CELLS (PROGENITOR CELLS THAT HAVE THE CAPACITY TO MIGRATE TO THE PERIPHERAL CIRCULATION AND TO DIFFERENTIATE INTO MATURE ENDOTHELIAL CELLS)
Infarction, Middle Cerebral Artery
Southern Medical University, ChinaCell therapyPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Infarction, Middle Cerebral Artery cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Plavix Xuanwu Hospital, Beijing | Phase 3 | BB |
Recombinant Human Plasminogen Activator SOS Attaque Cérébrale | Phase 4 | BB |
Recombinant Human Erythropoietin Alfa Max-Planck-Institute of Experimental Medicine | Phase 2/3 | B |
PHYSIOLOGIC SODIUM CHLORIDE SOLUTION Max-Planck-Institute of Experimental Medicine | Phase 2/3 | B |
Auto-Cd34+ Cells Imperial College London | Phase 1/2 | CCC |
Same molecule, other indications
AUTOLOGOUS ENDOTHELIAL PROGENITOR CELLS (PROGENITOR CELLS THAT HAVE THE CAPACITY TO MIGRATE TO THE PERIPHERAL CIRCULATION AND TO DIFFERENTIATE INTO MATURE ENDOTHELIAL CELLS) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →